Top 20 Biopharmaceutical Companies by 2022 Revenue.

 

SPECIAL REPORT

 

Top 20 Biopharmaceutical Companies by 2022 Revenue.

 

For the first time in biopharmaceutical history, a single company has exceeded the $100 billion mark in annual revenue. Pfizer passed that milestone figure supported by its sales of COVID-19 products. Comirnaty, the vaccine partnered with BioNTech made $37.8 billion sales whereas the oral antiviral Paxlovid reached $18.9 billion. Johnson & Johnson which occupied the first position for more than a decade comes in second place with sales of $94.9 billion and Roche makes the podium with sales of $66.26 billion. Both Roche and Johnson & Johnson are not pure biopharmaceutical players and have medical devices and diagnostic divisions with significant sales.

The ranking disclosed by Fierce Biotech shows one newcomer: the German Merck KGaA while the American Viatris is falling out. Within the Top 20 companies Fierce Biotech lists 10 European based companies, 9 American ones and 1 Japanese company.

With sales of COVID products expected to decrease significantly in 2023 this current ranking will be strongly affected in one year from now.

 

The full report is available upon request at jcm9144@gmail.com

1

Pfizer

2022 revenue: $100.33 billion
2021 revenue: $81.29 billion

2

Johnson & Johnson

2022 revenue: $94.94 billion
2021 revenue: $93.77 billion

3

Roche

2022 revenue: 63.28 billion Swiss francs ($66.26 billion)
2021 revenue: 62.80 billion Swiss francs ($68.71 billion)

4

Merck & Co.

2022 revenue: $59.28 billion
2021 revenue: $48.70 billion

5

AbbVie

2022 revenue: $58.05 billion
2021 revenue: $56.20 billion

6

Novartis

2022 revenue: $50.54 billion
2021 revenue: $51.63 billion

7

Bristol Myers Squibb

2022 revenue: $46.16 billion
2021 revenue: $46.38 billion

8

Sanofi

2022 revenue: 43.00 billion euros ($45.22 billion)
2021 revenue: 37.76 billion euros ($44.63 billion)

9

AstraZeneca

2022 revenue: $44.35 billion
2021 revenue: $37.42 billion
 

10

GSK

2022 revenue: 29.32 billion pounds ($36.15 billion)
2021 revenue: 34.11 billion pounds ($46.92 billion)10

 

11

Takeda Pharmaceutical Company

2022 revenue: 3,944 billion Japanese yen ($30.00 billion)
2021 revenue: 3,467 billion Japanese yen ($31.57 billion)

12

Eli Lilly

2022 revenue: $28.55 billion
2021 revenue: $28.32 billion

13

Gilead Sciences

2022 revenue: $27.28 billion
2021 revenue: $27.30 billion

14

Bayer

2022 revenue: 25.33 billion euros ($26.64 billion)
2021 revenue: 23.64 billion euros ($27.94 billion)

15

Amgen

2022 revenue: $26.32 billion
2021 revenue: $25.98 billion

16

Boehringer Ingelheim

2022 revenue: 24.04 billion euros ($25.28 billion)
2021 revenue: 20.51 billion euros ($24.24 billion)

17

Novo Nordisk

2022 revenue: 176.95 million Danish kroner ($25.00 billion)
2021 revenue: 140.80 million Danish kroner ($22.38 billion)

18

Moderna

2022 revenue: $19.26 billion
2021 revenue: $18.47 billion

19

Merck KGaA

2022 revenue: 18.22 billion euros ($19.16 billion)
2021 revenue: 16.07 billion euros ($19.11 billion)

20

BioNTech

2022 revenue: 17.31 billion euros ($18.20 billion)
2021 revenue: 18.98 billion euros ($22.43 billion

 

Paris, April 20, 2023

 

 

 

This document has been prepared by btobioinnovation and is provided to you for information purposes only.  The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change.  btobioinnovation has no obligation to update its opinions or the information in this document.

 

 

Share :
  •  
  •  
  •  
  •  
  •